afatinib
Boehringer and Sanofi admit to code breaches
February 13, 2015Medical Communications, Sales and Marketing ABPI, Boehringer, PMCPA, Sanofi, afatinib, giotrif
Sanofi and Boehringer Ingelheim have both admitted to breaching the ABPI Code of Practice, with Sanofi set to be publicly …
Boehringer lung cancer drug shows survival benefit
June 3, 2014Sales and Marketing ASCO, Boehringer, NSCLC, afatinib, giotrif, lung cancer
A new analysis of two late-stage trials shows that Boehringer drug Giotrif extends overall survival in a large proportion of …
Giotrif increases lung cancer survival
May 16, 2014Research and Development, Sales and Marketing Boehringer, Iressa, Roche, Tarceva, afatinib, giotrif, lung cancer
Boehringer Ingelheim is trumpeting overall survival results from a new analysis of two late-stage studies involving Giotrif in lung cancer …
Boehringer’s first cancer drug gains NICE yes
March 17, 2014Sales and Marketing Boehringer, Cancer, NICE, NSCLC, afatinib, giotrif
NICE is recommending that Boehringer Ingelheim’s first oncology treatment Giotrif be funded by the NHS. The new final draft guidance …
Boehringer nears European approval for first cancer drug
July 29, 2013Sales and Marketing Boehringer, Cancer, FDA, afatinib
Boehringer’s first cancer drug is just months away from being approved in Europe after a committee for the EMA gave …
FDA approves Boehringer’s lung cancer drug
July 12, 2013Medical Communications, Sales and Marketing Boehringer, FDA, Roche, Tarceva, afatinib, lung cancer
Boehringer Ingelheim’s late-stage lung cancer drug Gilotrif has received an accelerated FDA approval for patients with a certain genetic mutation. …
Boehringer submits new lung cancer drug
September 20, 2012Research and Development, Sales and Marketing Boehringer, NSCLC, Roche, Tarceva, afatinib
Boehringer Ingelheim has filed its new lung cancer drug with the EMA. Afatinib is the latest targeted therapy for lung …
Boehringer broadens afatinib studies
January 27, 2012Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, afatinib
Boehringer Ingelheim is expanding the scope of its studies into afatinib to test its use against head and neck cancers. …
Boehringer expands afatinib breast cancer trials
August 31, 2011Research and Development Boehringer, afatinib
Boehringer Ingelheim has begun two new phase II trials of its investigational cancer drug afatinib. The studies will cover afatinib’s …
No magic bullet, but a growing arsenal against lung cancer
February 23, 2011Research and Development ASA404, Cancer, Iressa, NSCLC, Tarceva, afatinib, crizotinib, figitumumab, lung cancer, non small cell lung cancer, non-small cell lung cancer
A man in his 70s is waiting for his appointment with the oncologist after being referred there by his family …
Boehringer puts afatinib head-to-head with Herceptin
December 10, 2010Research and Development BIBW 2992, Boehringer Ingelheim, Herceptin, Roche, Tovok, afatinib, breast cancer
Boehringer Ingelheim has set up a showdown between one of its pipeline oncology products and Roche’s Herceptin. It has started …
Latest content
Five Facts about cardiovascular disease
